WYOST (denosumab-bbdz)
Wyost (denosumab-bbdz) is a RANK ligand inhibitor used to manage bone-related complications in oncology patients. It is indicated to prevent skeletal-related events in individuals with multiple myeloma or bone metastases from solid tumors. Additionally, the drug is used for patients with hypercalcemia of malignancy that has not responded to bisphosphonate therapy and for certain cases of giant cell tumor of bone.
How WYOST Works
Wyost functions by binding to RANKL, a protein necessary for the formation and survival of osteoclasts, which are the cells responsible for bone resorption. By preventing RANKL from activating its receptor (RANK) on the surface of osteoclasts and their precursors, the drug inhibits the breakdown of bone and the subsequent release of calcium. This modulation of osteoclast activity helps address bone pathology and tumor growth associated with various malignancies.
Details
- Status
- Prescription
- First Approved
- 2024-03-05
- Patent Cliff
- 2025
- Routes
- SUBCUTANEOUS
- Dosage Forms
- INJECTABLE
WYOST Approval History
What WYOST Treats
4 indicationsWYOST is approved for 4 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Multiple Myeloma
- Bone Metastasis
- Giant Cell Tumor of Bone
- Hypercalcemia of Malignancy
Pharmacists can substitute WYOST for Prolia without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
WYOST Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in WYOST's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications WYOST treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to WYOST
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
WYOST FDA Label Details
Indications & Usage
FDA Label (PDF)WYOST is indicated for the treatment of Multiple Myeloma; Bone Metastasis; Giant Cell Tumor of Bone; Hypercalcemia of Malignancy.
Track WYOST with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.